Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

1.5K
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
1.5K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

476
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
476
Peripheral Artery Disease I: Introduction01:30

Peripheral Artery Disease I: Introduction

443
Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
443
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

1.3K
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.3K
Atherosclerosis IV: Nursing Management01:23

Atherosclerosis IV: Nursing Management

493
Nursing management for a patient with arteriosclerosis involves a comprehensive approach focusing on lifestyle modification, disease monitoring, education, and symptomatic care. Here is an overview of effective nursing strategies:Assessment and Monitoring: Initial and ongoing assessments are crucial. Nurses must document the patient's medical history, including any hypertension, diabetes, hyperlipidemia, and other cardiovascular diseases. Assessments also cover family history and lifestyle...
493
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

605
Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
605

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Use of advanced cardiovascular imaging in rheumatic immune-mediated inflammatory diseases.

Rheumatology (Oxford, England)·2026
Same author

EACVI survey on the use of multi-modality cardiovascular imaging in immune-mediated inflammatory diseases.

European heart journal. Imaging methods and practice·2026
Same author

[Low-dose interleukin-2: A potential immunotherapy for post-myocardial infarction patients].

Medecine sciences : M/S·2026
Same author

Molecular contrast agents for post-infarct cardiac remodelling: a contemporary review.

European heart journal. Imaging methods and practice·2026
Same author

Epigenetic Programming of Macrophage Phenotypes by STING-IRF3 Drives Inflammation in Ascending Thoracic Aortic Dissection.

bioRxiv : the preprint server for biology·2026
Same author

Anti-inflammatory therapy with low-dose IL-2 in acute coronary syndromes: a randomized phase 2 trial.

Nature medicine·2026

Related Experiment Video

Updated: Feb 23, 2026

Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice
09:06

Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice

Published on: February 20, 2019

8.9K

Plan B (-cell) in atherosclerosis.

Meritxell Nus1, Dimitrios Tsiantoulas1, Ziad Mallat2

  • 1Department of Medicine, Division of Cardiovascular Medicine, University of Cambridge, Cambridge, UK.

European Journal of Pharmacology
|September 9, 2017
PubMed
Summary

B cells have complex roles in atherosclerosis, with distinct subsets offering protective or harmful effects. Targeted therapies focusing on specific B cell subsets could improve cardiovascular risk management and treatment safety.

Keywords:
AntibodiesAtherosclerosisB cellsImmune systemLymphocytesTherapy

More Related Videos

Induction of Atherosclerotic Plaques Through Activation of Mineralocorticoid Receptors in Apolipoprotein E-deficient Mice
07:36

Induction of Atherosclerotic Plaques Through Activation of Mineralocorticoid Receptors in Apolipoprotein E-deficient Mice

Published on: September 26, 2018

10.6K
A Human Ex Vivo Atherosclerotic Plaque Model to Study Lesion Biology
05:51

A Human Ex Vivo Atherosclerotic Plaque Model to Study Lesion Biology

Published on: May 6, 2014

13.8K

Related Experiment Videos

Last Updated: Feb 23, 2026

Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice
09:06

Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice

Published on: February 20, 2019

8.9K
Induction of Atherosclerotic Plaques Through Activation of Mineralocorticoid Receptors in Apolipoprotein E-deficient Mice
07:36

Induction of Atherosclerotic Plaques Through Activation of Mineralocorticoid Receptors in Apolipoprotein E-deficient Mice

Published on: September 26, 2018

10.6K
A Human Ex Vivo Atherosclerotic Plaque Model to Study Lesion Biology
05:51

A Human Ex Vivo Atherosclerotic Plaque Model to Study Lesion Biology

Published on: May 6, 2014

13.8K

Area of Science:

  • Cardiovascular Science
  • Immunology
  • Inflammation Biology

Background:

  • Atherosclerosis is a major global cause of mortality.
  • It is characterized by chronic inflammation involving vascular, circulating, and immune cells.
  • B cells are key immune players in chronic inflammation, influencing antibody production and T/NK cell activity.

Purpose of the Study:

  • To review the multifaceted roles of B cell subsets in atherogenesis.
  • To highlight the potential cardiovascular implications of B cell-targeted therapies.
  • To advocate for the development of B cell subset-specific treatments.

Main Methods:

  • Literature review of B cell subsets in atherosclerosis.
  • Analysis of existing data on B cell functions in atherogenesis.
  • Evaluation of current and potential B cell-targeted therapies.

Main Results:

  • Distinct B cell subsets exhibit both atherogenic and protective functions in atherosclerosis.
  • B cell depletion or modulation is utilized in treating autoimmune diseases.
  • Current B cell therapies may impact cardiovascular risk in treated patients.

Conclusions:

  • Understanding B cell subset roles is crucial for managing atherosclerosis.
  • B cell-targeted therapies offer potential for cardiovascular risk modification.
  • Developing subset-specific therapies can enhance treatment efficacy and safety.